Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Intralesional triamcinolone acetonide is effective for treating patchy hair loss, and dermoscopy helps detect treatment response and side effects early.

Topical anthralin helped regrow hair in mice with a condition similar to human alopecia.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Superficial cryotherapy is effective and safe for treating alopecia areata, with better results when used early and frequently.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

The combination therapy was effective and well-tolerated, especially in young patients.

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.

Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.

Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.

Mice treatments didn't grow hair, a patient treatment may affect immune response, and people with hair loss often feel anxious or depressed.

The herbal mixture could potentially improve hair loss.

Topical immunotherapy is the best treatment for severe alopecia areata.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Erdr1 could be a new marker for diagnosing hair loss.

Topical contact sensitizers can treat certain skin conditions but are rarely used in the U.K.

Some treatments like pentoxifylline with topical corticosteroids might work for alopecia areata, but more research is needed to find the best one.

The document concludes that various childhood hair and nail disorders exist, some may improve on their own, and advances in genetics and immunology could enhance treatment and counseling.

The document concludes that hair loss is complex, affects many people, has limited treatments, and requires more research on its causes and psychological impact.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.